Sciclone Pharmaceuticals Inc
SCLN
SCLN was delisted on the 13th of October, 2017.
96 hedge funds and large institutions have $122M invested in Sciclone Pharmaceuticals Inc in 2014 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 33 increasing their positions, 40 reducing their positions, and 9 closing their positions.
4% less funds holding
Funds holding: 100 → 96 (-4)
14% less capital invested
Capital invested by funds: $142M → $122M (-$20.3M)
18% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 40
44% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 9
90% less call options, than puts
Call options by funds: $15K | Put options by funds: $146K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$1.1M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$712K |
| 3 |
QBFM
QS Batterymarch Financial Management
New York
|
+$644K |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$390K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$349K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$2.21M |
| 2 |
Millennium Management
New York
|
-$1.78M |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$1.76M |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$1.12M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.08M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TC
101
TFS Capital
West Chester,
Pennsylvania
| – | -$212K | -42,157 | Closed |
|
102
Tudor Investment Corp
Stamford,
Connecticut
| – | -$180K | -35,700 | Closed |
|
|
PC
103
Passport Capital
San Francisco,
California
| – | -$68K | -13,513 | Closed |
|
|
RCM
104
Rotella Capital Management
Bellevue,
Washington
| – | -$57K | -11,272 | Closed |
|
|
HF
105
Hoxton Financial
Shepherdstown,
West Virginia
| – | -$3K | -659 | Closed |
|
SCLN Hedge Fund Activity: Q1 2014 in Review
96 of the 3,463 institutional investors tracked by Wall St. Rank reported a position in Sciclone Pharmaceuticals Inc (SCLN) for Q1 2014, worth a combined $122M — down 14% from $142M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of SCLN and 5 opened new positions — a net loss of 4 holders — while 40 trimmed existing stakes and 33 added.
The largest buyer was Nantahala Capital Management, adding an estimated $1.1M. The largest seller was JP Morgan Chase, exiting entirely with an estimated $2.21M sold.
- 96 institutional investors held Sciclone Pharmaceuticals Inc (SCLN) as of Q1 2014, down from 100 in Q4 2013.
- Funds reported $122M of Sciclone Pharmaceuticals Inc stock for Q1 2014, down 14% quarter-over-quarter.
- 5 funds opened new Sciclone Pharmaceuticals Inc positions in Q1 2014 and 9 closed out, a net change of -4 holders.
- The largest Sciclone Pharmaceuticals Inc buyer in Q1 2014 was Nantahala Capital Management, an estimated $1.1M added.
- The largest Sciclone Pharmaceuticals Inc seller in Q1 2014 was JP Morgan Chase, an estimated $2.21M sold.
Based on aggregated 13F filings for Q1 2014.